Response and outcomes of patients with IDH1/2- mutated accelerated/blast-phase myeloproliferative neoplasms
Leah Goldberg(University of Chicago Medical Center), Anand Patel(Ascension), Ellen Madarang(University of Miami), Madelyn Burkart(Atrium Health Wake Forest Baptist), Alexa J. Siddon(Yale University), Yasmin Abaza(Northwestern University), Marta Davidson(Princess Margaret Cancer Centre), Joshua Kassner(Memorial Sloan Kettering Cancer Center), John Cursio, Hannah Johnston(University of Illinois Chicago), Jacqueline S. Garcia(Dana-Farber Cancer Institute), Evan C. Chen(Dana-Farber Cancer Institute), Olatoyosi Odenike(University of Chicago), Kristen Pettit(University of Michigan), Terrence Bradley(University of Miami Health System), Vikas Gupta(Indian Institute of Technology Kanpur), James Yoon(Beth Israel Deaconess Medical Center), Raajit K. Rampal(Memorial Sloan Kettering Cancer Center), Sunil Iyer(University of Miami), Chandrasekar Muthiah(Medical College of Wisconsin), Rory M. Shallis(Smilow Cancer Hospital), Timothy S. Oh(Northwestern University), Guru Subramanian Guru Murthy(Medical College of Wisconsin)
Cited by 5
Related Papers
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.8k
The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice
|Cancer Cell|2016|304